Document Detail

Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis.
MedLine Citation:
PMID:  11191719     Owner:  NLM     Status:  MEDLINE    
We evaluated the effect of 12 months of 300-mg oral sarpogrelate hydrochloride (SH) once daily on the symptoms of Raynaud's phenomenon, respiratory failure and cardiac function in seven patients with systemic sclerosis. Arterial blood gases, pulmonary function, mean pulmonary arterial pressure, left ventricular ejection fraction (LVEF), right ventricular ejection fraction (RVEF), white blood cell count, C-reactive protein and the plasma concentrations of fibrinopeptide A, beta-thromboglobulin, platelet factor 4 and thrombomodulin were evaluated before and 2 and 12 months after SH administration. After 2 and 12 months of SH administration, a significant decrease was found in the frequency and duration of Raynaud's phenomenon, as well as the coldness, numbness and pain of Raynaud's phenomenon. Respiratory failure, as estimated by Hugh-Jones classification, was significantly decreased, whereas the percentage carbon monoxide diffusion capacity was significantly increased. The mean pulmonary arterial pressure decreased significantly, as did plasma fibrinopeptide A, beta-thromboglobulin and platelet factor 4. There was no significant change in LVEF after 2 or 12 months, but after 12 months of SH administration, RVEF increased significantly. In conclusion, use of SH may prevent Raynaud's phenomenon, respiratory failure and right ventricular failure in patients with systemic sclerosis.
S Kato; I Kishiro; M Machida; D Fuse; T Yoshida; N Kaneko
Related Documents :
18082509 - Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistan...
831959 - The pathophysiological changes of experimental fat embolism: early pre-hypoxaemic changes.
12803589 - Milrinone improves lung compliance in patients receiving mechanical ventilation for car...
12760589 - The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmona...
15490569 - Pulmonary arterial pressure in children with allergic rhinitis.
3751929 - Effects of ci-914 in congestive heart failure due to coronary artery disease or idiopat...
11332329 - Relationship between alcohol consumption, ambulatory blood pressure recordings and left...
10806149 - The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced ...
16467579 - Targeted disruption of the blood-brain barrier with focused ultrasound: association wit...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of international medical research     Volume:  28     ISSN:  0300-0605     ISO Abbreviation:  J. Int. Med. Res.     Publication Date:    2000 Nov-Dec
Date Detail:
Created Date:  2001-01-12     Completed Date:  2001-03-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0346411     Medline TA:  J Int Med Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  258-68     Citation Subset:  IM    
Department of Cardiology and Pneumology, Dokkyo University School of Medicine,Tochigi Prefecture, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hypertension, Pulmonary / etiology,  prevention & control*
Middle Aged
Raynaud Disease / etiology,  prevention & control
Respiratory Insufficiency / etiology,  prevention & control*
Scleroderma, Systemic / complications,  drug therapy*
Serotonin Antagonists / therapeutic use*
Succinates / therapeutic use*
Time Factors
Ventricular Dysfunction, Right / etiology,  prevention & control*
Reg. No./Substance:
0/Serotonin Antagonists; 0/Succinates; 86819-20-7/sarpogrelate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for...
Next Document:  Lonidamine cytotoxicity: involvement of the lysosomal compartment.